Horizon Health Technology Limited – Trademark Portfolio
Entity Type: 03
Horizon Health Technology Limited holds 4 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 3 filings in this category. The portfolio also extends into Class 30 (Staple Foods) across 2 Nice Classification classes. Currently, 3 trademarks are registered. Notable registered marks include SUNPON, PENGSAN, and NADOVATE. The owner is based in Denver, CO.
1312 17TH ST UNIT NUM2955
Denver, CO 80202
Showing of trademarks Trademarks
Trademark Classifications
Horizon Health Technology Limited's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Coffee, tea, cocoa and artificial coffee; rice; tapioca and sago; flour and preparations
Frequently Asked Questions
How many trademarks does Horizon Health Technology Limited have?
Horizon Health Technology Limited has 4 U.S. trademarks filed with the USPTO. Of these, 3 registered, 1 abandoned.
What trademark classes does Horizon Health Technology Limited file in?
Horizon Health Technology Limited files trademarks across 2 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 30 (Staple Foods). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are Horizon Health Technology Limited's most well-known trademarks?
Horizon Health Technology Limited's registered trademark portfolio includes well-known marks such as SUNPON, PENGSAN, and NADOVATE. These are among 3 currently registered trademarks in the portfolio.
What is Horizon Health Technology Limited's trademark registration success rate?
Horizon Health Technology Limited has a 75% trademark registration rate, with 3 out of 4 resolved applications resulting in successful registration. Currently, 0 applications are pending review.